Feb. 23 at 8:40 PM
Projected PDAC Blockbusters:
$RVMD &
$IMRX - via Nature dot com:
RAS inhibitors are projected to be the top-selling class (
$3.8 billion), driven entirely with daraxonrasib [RVMD], whereas MEK inhibitors are expected to generate
$1.5 billion, exclusively from atebimetinib [IMRX].
https://www.nature.com/articles/d41573-026-00027-3
'The Pancreatic Cancer Drug Market:'
"By 2034, RAS inhibitors are projected to be the top-selling class (
$3.8 billion), driven entirely with daraxonrasib, whereas MEK inhibitors are expected to generate
$1.5 billion, exclusively from atebimetinib. Driven by its extended use as a first-line chemotherapy regimen and its evaluation in combination with novel emerging therapies, gemcitabine plus nanoparticle paclitaxel is projected to drive sales to nearly
$2 billion. The pNET market is forecast to reach nearly
$1 billion by 2034, with radiolabeled somatostatin analogues and TKIs together contributing approximately
$460 million.
$BMY $LLY